drugset
drugset / Trial / NCT02916901

Study to Investigate the Influence of CKD-519 on 24-h Ambulatory Blood Pressure in Healthy Adult Volunteers

NCT02916901 ↗

Phase 1 Completed 32 enrolled Chong Kun Dang Pharmaceutical
RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of this study is to determine influence of CKD-519 on 24-h ambulatory blood pressure after oral administration in healthy adult volunteers.

Timeline

Start
2016-08
Primary completion
2016-10
Completion
2017-01

Drugs

EvaluationDrugModalityDoseRoute
Subject ROCACETRAPIB Small molecule 200 mg Oral

Indications

No indication recorded.